Nxgen MDX, LLC

Nxgen MDX, LLC was paid $21.47M by Medicaid between Jan 2018 and Dec 2024, across 80 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Michigan

Rank by total paid#9 of 108

Median peer was paid$588K

This provider vs. median37×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	45,503	$4.76M
2019	48,810	$3.41M
2020	79,063	$3.63M
2021	91,828	$3.04M
2022	90,159	$2.39M
2023	69,719	$2.64M
2024incomplete	45,503	$1.61M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	15%	47,504	36,199	$3.23M
81220	CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants	13%	14,770	12,619	$2.84M
81420	Fetal chromosomal aneuploidy genomic sequence analysis panel	13%	18,102	16,174	$2.71M
81223		7.3%	593	583	$1.57M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	5.9%	10,229	9,488	$1.26M
87481		3.4%	16,767	15,217	$732K
81222		3.1%	6,784	5,849	$659K
81259		2.3%	3,903	3,344	$501K
81405		2.3%	7,148	4,084	$500K
81249		1.7%	2,866	2,451	$363K
81406		1.7%	9,465	3,240	$360K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	1.7%	6,840	5,921	$356K

68 more codes

81243		1.5%	13,075	$317K
81408		1.4%	3,656	$311K
81514		1.3%	4,848	$274K
81336		1.3%	6,060	$271K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.2%	14,706	$265K
87653		1.2%	22,106	$257K
87529		1.2%	19,605	$257K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	1.2%	19,343	$256K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.2%	19,019	$253K
87500		1.2%	22,183	$252K
81407		1.0%	1,376	$222K
81255		<1%	1,786	$213K
87640		<1%	17,246	$212K
81329		<1%	8,776	$205K
87563		<1%	17,864	$200K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	15,519	$183K
81404		<1%	3,041	$178K
81224		<1%	6,800	$168K
87511		<1%	14,621	$165K
81200		<1%	3,543	$145K
81330		<1%	3,591	$131K
81209		<1%	3,610	$125K
81244		<1%	5,197	$124K
81251		<1%	3,685	$123K
81260		<1%	3,165	$120K
81290		<1%	3,679	$119K
81401		<1%	4,805	$110K
81364		<1%	3,868	$97K
81479	Unlisted molecular pathology procedure	<1%	15,206	$85K
81400		<1%	5,732	$81K
81250		<1%	3,770	$56K
81242		<1%	3,718	$56K
87506		<1%	852	$52K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	673	$50K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	1,118	$50K
81252		<1%	1,620	$47K
81443		<1%	624	$41K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	346	$37K
87486		<1%	1,106	$37K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	734	$30K
81402		<1%	871	$25K
87505		<1%	1,015	$23K
81205		<1%	1,831	$20K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	131	$14K
81361		<1%	736	$12K
81257		<1%	121	$11K
85041		<1%	1,434	$10K
83021		<1%	1,638	$10K
85014		<1%	1,438	$10K
85018		<1%	1,437	$10K
86780		<1%	879	$6K
87186		<1%	1,611	$6K
87641		<1%	1,113	$5K
87541		<1%	1,111	$5K
87532		<1%	1,112	$5K
87498		<1%	1,111	$5K
87150		<1%	868	$5K
81269		<1%	179	$4K
87580		<1%	1,109	$4K
G0452	Molecular pathology procedure; physician interpretation and report	<1%	1,594	$3K
81241		<1%	317	$3K
81240		<1%	333	$3K
83020		<1%	441	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	184	$2K
87634		<1%	81	$1K
81254		<1%	468	$1K
82955		<1%	120	$802.51
36415	Collection of venous blood by venipuncture	<1%	59	$25.43

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialMACK, ALAN (PRESIDENT/CEO)